• The cholinergic muscarinic inhibitor scopolamine impairs interval timing behavior.
Introduction resistant to differences in overall response rate [11, [24] [25] [26] . Curvature indices and response rates were compared between the normal saline and the scopolamine groups using a two-tailed t-test;
p<0.05 was interpreted as statistically significant.
Surgical procedures: Mice trained in the 12-sec fixed-interval-timing task were implanted with recording microelectrode arrays (Microprobes) targeting the MFC prior to neurophysiology recordings. Briefly, mice were anesthetized using ketamine (100 mg/kg) and xylazine (10 mg/kg).
A surgical level of anesthesia was maintained, with ketamine supplements (10 mg/kg) given hourly (or as needed) and regular monitoring for stable respiratory rate and absent toe pinch response. Mice were placed in the stereotactic equipment with non-rupturing ear bars. A heating pad was used to prevent hypothermia. Under aseptic surgical conditions, the skull was leveled between the bregma and lambda. A single craniotomy was drilled over the area above the MFC and three holes were drilled for skull screws. For recording experiments, animals were implanted (coordinates from the bregma: AP: +1.8, ML + 0.5, DV -1.8) with a microelectrode array configured as a 4x4 array of 50 μ m stainless steel wires (200 μ m between wires and rows;
impedance measured in vitro at 400-600 kΩ; Microprobes). Electrode ground wires were wrapped around the skull screws. The electrode array was inserted while concurrently recording neuronal activity. The craniotomy was sealed with cyanoacrylate ("SloZap", Pacer Technologies) accelerated by "ZipKicker" (Pacer Technologies), and methyl methacrylate ("dental cement"; AM Systems). Following implantation, animals were allowed to recover for two weeks before being reacclimatized to behavioral and recording procedures.
Neuronal ensemble recordings: Freely moving electrophysiological recordings were performed as described in detail previously [11, 24] . Following training in a 12-sec interval timing task and MFC implantation with 16-channel microelectrodes, mice were subjected to intraperitoneal injection with normal saline or scopolamine (1mg/kg, Sigma-Aldrich, S0929) while being recorded during the 12-sec interval timing task. Mice were connected to recording head stages and a cable without anesthesia. Neuronal ensemble recordings in the MFC were made using a multi-electrode recording system (Open Ephys). Raw wideband signal was high-pass filtered at 0.05Hz with total gain of 5000, and recorded with 16-bit digitization at 30k Hz sampling rate. To detect spikes, raw signals were rereferenced using common median referencing to minimize potential non-neural electrical noise, and band-pass filtered between 300 and 6000 Hz offline.
Spikes were detected with a threshold of 5 median absolute deviations. A Plexon Offline Sorter was used to sort single units and to remove artifacts. PCA and waveform shape were used for spike sorting. Single units were identified as having 1) consistent waveform shape, 2) separable clusters in PCA space, 3) a consistent refractory period of at least 1 ms in inter-spike-interval histograms, and 4) consistent firing rates around behavioral events. Unique neurons were verified by constructing two-dimensional cumulative distribution probabilities from Pearson's correlation coefficients of pair-wise waveform and inter-spike-interval comparisons, and using a one-tailed threshold of p<0.05. Spike activity was analyzed for all cells that fired at rates above 0.1 Hz.
Local field potential (LFP) was recorded with bandpass filters between 0.05 and 1000 Hz.
Statistical summaries were based on all recorded neurons. No subpopulations were selected or filtered out of the neuron database. Analysis of neuronal activity and quantitative analysis of basic firing properties were carried out with custom routines for MATLAB (all raw data and MATLAB scripts are available at our lab website: https://narayanan.lab.uiowa.edu/ article/datasets). All behavioral events were recorded simultaneously using TTL inputs at 30k Hz.
Peri-event rasters and average histograms were constructed around trial start.
We analyzed our neuronal data according to procedures described at length previously [11, 24] . For each neuron, we constructed peri-event spike data from -2 sec to 12 sec after trial start. As in the past, we defined time-related ramping neurons as those with a significant fit via linear regression of time vs. firing rate over the interval binned at 1 sec. Finally, we defined stimulus-modulated and response-modulated neurons as those with trial-by-trial changes in firing rate 0-200 msec after event onset compared to -500 to -300 msec prior to stimulus onset with a p<0.05 via a paired t-test. Pearson's chi-squared test was used to compare the number of modulated neurons between saline and scopolamine sessions.
We analyzed neuronal patterns using PCA, which we have used to identify patterns of neuronal activity in an unbiased, data-driven manner [11, [27] [28] [29] . PCA was constructed from ztransformed peri-event time histograms over the entire interval binned at 0.1 sec and smoothed with a gaussian kernel over 5 bins. All neurons from 8 mice from sessions with saline or scopolamine infusions were included in PCA. We then used a t-test to compare PCs between saline and scopolamine sessions.
MFC LFP power was calculated in defined frequency bands (delta: 1-4 Hz, theta: 5-8 Hz; alpha: 9-12 Hz; beta: 13-30 Hz) during the interval (0-12 s) using wavelet-based time-frequency analyses.
Histology: When experiments were complete, mice were euthanized by injections of 100 mg/kg sodium pentobarbital. All mice were intracardially perfused with 4% paraformaldehyde. The brain was removed and post-fixed in paraformaldehyde overnight and immersed in 30% sucrose until the brains sank. Sections (40 µm) were made on a cryostat (Leica) and stored in cryoprotectant (50% PBS, 30% ethylene glycol, 20% glycerol) at -20°C, before being mounted onto slides with mounting media containing DAPI (Invitrogen P36962). Images were captured on an Olympus VS120 Microscope.
Results

Scopolamine impairs fixed-interval timing
Two past studies in rodents have demonstrated that scopolamine impairs interval timing [20, 21] .
During neuronal recording sessions, we found that scopolamine infusion markedly changed timeresponse histograms during fixed-interval timing ( Fig 1C) . We calculated the curvature of timeresponse histograms to measure timing, a metric based on cumulative distribution functions that we and others have used in the past [11, [24] [25] [26] . We found that scopolamine significantly decreased the curvature of time-response histograms (0.25 +/-0.02 vs. 0.03 +/-0.03 with scopolamine; paired t (7) =5.1, p=0.001; Fig 1D) . Furthermore, we noticed that there were more responses early in the interval and that scopolamine decreased the ratio of responses late in the interval vs. early in the interval (last 6 sec divided by first 6 sec; 3.27 +/-0.31 vs. 1.60 +/-0.26 with scopolamine, paired t (7) =3.9, p=0.006; Fig 1E) . Scopolamine did not change the number of overall responses between 0 and 12 sec (86.3 +/-23.0 vs. 98.4 +/-28.5 with scopolamine) or the number of rewards (66.6 +/-5.3 vs. 63.8 +/-5.3 with scopolamine). Taken together, our findings are consistent with past work demonstrating that scopolamine impairs interval timing [20, 21] .
Scopolamine does not change MFC ramping but increases stimulus-related processing.
Prior work by our group and others has demonstrated that time-related ramping activity by MFC neurons is a key correlate of temporal processing [16, 23] . As scopolamine impairs interval timing, we hypothesized that this drug would impair time-related ramping. We tested this idea by identifying time-related ramping MFC neurons by linear regression (Fig 2A) , and comparing the number of MFC ramping neurons in sessions with saline and scopolamine. In 8 mice, of 117 MFC neurons recorded during saline sessions, 41 exhibited time-related ramping (35%).
Critically, a similar fraction of MFC neurons exhibited ramping with scopolamine (36 of 108, or 33%); this did not support our hypothesis.
Next, we looked at other modulation patterns in MFC. Prefrontal regions can powerfully affect stimulus-processing [30] [31] [32] . During fixed-interval timing, this stimulus is a light that goes on at trial start ( Fig 2B) . Surprisingly, there were twice as many stimulus-modulated MFC neurons in scopolamine sessions (32 of 108, or 30%) compared to saline sessions (16 of 117, or 14%; X 2 =7.6, p=0.006). There were no differences in the number of response-modulated neurons ( Figure 2C ; 39% with saline vs. 44% with scopolamine). These data provide evidence that neither MFC ramping nor response-related activities are changed by scopolamine; by contrast, scopolamine increased MFC stimulus-related modulation.
When comparing average MFC neuronal ensemble activity in saline and scopolamine sessions, we noticed subtle differences late in the interval (increased activity at black arrow in Fig 3A vs . decreased activity at black arrow in Fig 3B) . These resulted in different average activities of MFC neuronal ensembles with saline vs. scopolamine ( Fig 3C) . To capture these differences with data-driven techniques, we turned to principal component analysis, which have been used extensively to identify patterns in complex neuronal data [11, [27] [28] [29] . We found three common patterns. PC1, which explained 29% of variance, exhibited time-related ramping activity, consistent with extensive past work from our group ( Fig 3D-E ). Of note, this component did not change with scopolamine, consistent with our results above and contrary to our hypothesis. PC2, which explained 19% of variance, was broadly modulated across the interval, and also did not change with scopolamine. By contrast, PC3, which explained 12% of variance, had a more complex pattern, with a peak close to 7 sec in the interval. Of note, in the scopolamine sessions there was a more negative score with PC3 compared to saline sessions (Fig 3F, PC3; t (223) =2.4, p<0.02). These data provide further evidence that scopolamine did not change MFC ramping but could change more complex aspects of MFC neuronal ensemble activity.
Finally, we examined MFC LFP oscillatory power during the interval (0-12 s; Figure 4 ).
We found no consistent changes in delta (1-4 Hz), theta (5-8 Hz), alpha (9-12 Hz), or beta activity (13-30 Hz). In summary, our results suggest that scopolamine impaired interval timing and enhances stimulus-related processing in MFC without changing MFC temporal processing or MFC LFPs.
Discussion
We tested the hypothesis that scopolamine would attenuate time-related ramping activity in the MFC. We found no evidence that scopolamine changed MFC ramping by linear regression or PCA. To our surprise, we found that stimulus-related processing was increased in the MFC with scopolamine. These data provide insight into how scopolamine might influence cortical circuits during interval timing.
Many cognitive behaviors are impaired by the muscarinic cholinergic inhibitor scopolamine, often through attentional and stimulus-processing deficits [33, 34] . Scopolamine reliably causes timing deficits in rodents [20, 21] , and here we report similar deficits during fixed-interval timing. Surprisingly, MFC ramping is intact with scopolamine administration.
There are two possibilities that might account for this result. First, we and others have identified neuronal ramping as a key mechanism of temporal processing in the MFC [16, 22, 23, 35] , but it is possible that ramping is not explicitly related to timing. In this case, others have proposed temporal computations based on oscillatory activity [36] , and we note that PC3 has oscillatory features, although the period appeared to be longer than 1 second. Scopolamine may affect neuronal oscillatory activity that was not detected by our analyses. A second possibility is that scopolamine affects stimulus-processing mechanisms in the MFC and this triggers animals to respond despite intact MFC temporal processing [31, 37] . The increase in responses early in the interval is supportive of this idea.
Previous studies have shown that acetylcholine is crucial for stimulus processing.
Microdialysis has revealed that acetylcholine is increased during tasks involving sustained attention, changes in ambient light, anticipation of a meal, motor activity, and handling, while amperometry has indicated that MFC acetylcholine can increase for reward-predictive cues [38] [39] [40] [41] [42] [43] . Acetylcholine can also be increased during attentionally demanding tasks such as 5-choice serial reaction-time tasks [31, 44] . Lesioning of MFC cholinergic projections impairs the processing of fast but not slow stimuli, as well as causing marked deficits in visual attentional performance [45] . To our knowledge MFC cholinergic projections have never been studied in interval timing, although cholinergic projections to the visual cortex affect learning of temporal intervals but not interval-timing performance [46] . Lesioning of MFC cholinergic projections decreased stimulus-related activity and the performance of a visual attention task, contrary to our results here with scopolamine, a muscarinic antagonist [47] . In primates, cholinergic deafferentation can affect working memory, and cholinergic effects on working memory and attention occur as a result of the direct effects on stimulus processing [48, 49] . These studies broadly support a role for cortical cholinergic circuits in task-related stimulus processing.
Our results here are quite different from those for systemic or focal manipulations of dopaminergic circuits in the frontal cortex or striatum [12, 27, 50, 51] . While dopaminergic manipulations also reliably affect interval timing, our work indicates that manipulating prefrontal dopamine via D1-type dopamine receptors affects both time-related ramping activity and ~4 Hz rhythms [11, 27] . Scopolamine appears to have distinct effects on MFC circuits enhancing stimulus-related activity while leaving MFC ramping and MFC LFPs unchanged. These data suggest that cholinergic and dopaminergic manipulations have distinct and specific effects on cortical circuits. Future studies with cell-type specific resolution might be able to further resolve themes of cortical cholinergic vs. dopaminergic circuits.
Patients with AD and PD have deficits in timing [10, 11, 15, [52] [53] [54] . We are not aware of studies of interval timing in DLB patients. PD and AD have prominent cholinergic deficits [1, 2] .
Of note, cholinergic drugs can improve cognition in patients with AD, PD and DLB [55].
However, little is known about the relevant cholinergic circuit mechanisms of these effects.
Our study has several limitations. First, scopolamine was administered systemically and is a poor model of cognitive dysfunction in dementia, as it can act on all muscarinic acetylcholine receptors in the brain [33] and other brain systems [56] . Furthermore, it can have non-specific locomotor and autonomic effects, although we did not observe an increased response rate and observed highly specific neuronal effects on stimulus-processing in this study.
Cholinergic interneurons in the striatum or the MFC may also be critical mediators of cognitive processing [57] . Finally, we are unsure if scopolamine directly modulates MFC stimulus-related neurons or modulates other brain areas. Nevertheless, our results lay important groundwork for highly specific investigation of cholinergic circuits using cell-type specific methods in future work.
In conclusion, we performed neuronal ensemble recording from the MFC of freely moving rodents, and found that muscarinic cholinergic inhibition caused timing deficits and hyper-stimulus-modulation during interval timing. MFC temporal processing was not significantly affected. These results are consistent with the consensus that acetylcholine plays major roles in attention, working memory and stimulus processing, while the dopaminergic system is crucial for the neuronal "ramping" activities and an internal pacemaker.
Neuromodulation therapies targeting the cholinergic circuits have potential as treatments for AD as well as DLB [55] . Data from this study will help us understand the cholinergic circuits and may have relevance for diseases involving cholinergic deficits, such as AD and DLB.
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There are no conflicts of interests. during the interval shown for all MFC neurons treated with saline, and B) scopolamine, sorted by peak activity. We noticed subtle differences in activity, with more activity in saline (arrow in A), vs. less activity in scopolamine (arrow in B) late in the interval. Activity binned at 10 ms and smoothed over 5 bins. C) There were differences during the interval between average MFC neuronal activities in saline vs. scopolamine sessions. D) To quantify these differences using data-driven techniques, we turned to principal component analysis, which identified 3 major patterns. PC1 had ramping patterns, PC2 was modulated during the interval, and PC3 had more complex modulation. E) Fraction of variance explained by each component. F) Only PC3 was different between saline and scopolamine sessions. Data from 8 mice; 117 MFC neurons recorded in saline sessions and 108 neurons recorded in scopolamine sessions; * =p<0.05 via ttest.
Figure 4. Scopolamine does not change MFC LFP activity:
We measured MFC LFPs from 8 mice in delta, theta, alpha, and beta power in saline and scopolamine sessions. We did not observe consistent differences between saline and scopolamine sessions. Data from 8 mice. 
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